Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 30 at 1:25 PM
$BIB RSI: 56.20, MACD: 1.5568 Vol: 2.86, MA20: 83.07, MA50: 81.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 21 at 6:53 PM
$CMPS Cute. Let's see how long this stays under seven dollars after topline. $ATAI $DFTX $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 20 at 2:56 PM
$CMPS https://youtu.be/4V7C_bdsu1Q?si=A8iz0VNREGDvaTGU every day that goes by is a day closer.... by Q1 we get topline for comp006. It works, topline from June was excellent, we'll just need dosing which is pending phase 3. Done deal. We'll be first to market. $ATAI $DFTX $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 15 at 9:45 PM
$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $DFTX $IBB $BIB
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:14 PM
$BIB $CMPS $IBB $DFTX $SNDL DEA WOULD BE FORECED TO RECLASSIFY PSILOCYBIN (ONLY THE $CMPS VERSION APPROVED BY THE FDA, IT WOULD NOT BE A GENERAL RECLASSIFICATION) = AFTER FDA APPROVAL AWAY FROM CLASS 1. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $DFTX
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:09 PM
$CMPS $SNDL $CMPS Q1 2026 pending phase 3 topline imminent for COMP 360. I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class." Maybe this is the reason = "COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $DFTX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:18 AM
$SNDL Dumb ass shorts posting dumb shit, one little bible thumper study, & he thinks it nullifies an Executive order, no son... your stupid... @Slickerthanall187, and the dumbass puts, shorts shares borrowed, or sold calls... also stupid, every day that passes brings us closer to class 3, super smart guy. ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted 1 of them below, the breast cancer 1 , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:13 AM
$SNDL ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted ONE of them below, the breast cancer one , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." Aug 2025 https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
Iman133
Iman133 Jan. 13 at 8:49 PM
$BIB $IBB $LXRX I think it is good thing because FDA doesn’t understand what does the p-value mean. They reject when p= 0.051 and accept p=0.049 At least we get rid of p-value here
0 · Reply
Latest News on BIB
Investing In Health Stocks - How Policy Clarity Is Opening Doors

Nov 11, 2025, 10:13 AM EST - 2 months ago

Investing In Health Stocks - How Policy Clarity Is Opening Doors

AGNG ARKG BBC BBH BBP BIS BMED

BIB: A Tactical 2 X Leveraged Biotech ETF

Oct 23, 2025, 8:00 AM EDT - 3 months ago

BIB: A Tactical 2 X Leveraged Biotech ETF

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 8 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIS BMED

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 1 year ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBC BBH BBP

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

Jul 30, 2024, 2:30 AM EDT - 1 year ago

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

AAPL AMZN ANSS BA FFIV GOOGL HSY

Equity CEFs/ETFs: Top Picks For 2024 - Part II

Jan 5, 2024, 11:01 AM EST - 2 years ago

Equity CEFs/ETFs: Top Picks For 2024 - Part II

AIO AIQ DIG EOI ETW EXG HQH

Why Now Could Be The Time To Consider Neuroscience Investments

Aug 27, 2022, 4:45 AM EDT - 3 years ago

Why Now Could Be The Time To Consider Neuroscience Investments

ARKG BBH FBT GNOM HELX IBB IBBQ

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 30 at 1:25 PM
$BIB RSI: 56.20, MACD: 1.5568 Vol: 2.86, MA20: 83.07, MA50: 81.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 21 at 6:53 PM
$CMPS Cute. Let's see how long this stays under seven dollars after topline. $ATAI $DFTX $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 20 at 2:56 PM
$CMPS https://youtu.be/4V7C_bdsu1Q?si=A8iz0VNREGDvaTGU every day that goes by is a day closer.... by Q1 we get topline for comp006. It works, topline from June was excellent, we'll just need dosing which is pending phase 3. Done deal. We'll be first to market. $ATAI $DFTX $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 15 at 9:45 PM
$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $DFTX $IBB $BIB
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:14 PM
$BIB $CMPS $IBB $DFTX $SNDL DEA WOULD BE FORECED TO RECLASSIFY PSILOCYBIN (ONLY THE $CMPS VERSION APPROVED BY THE FDA, IT WOULD NOT BE A GENERAL RECLASSIFICATION) = AFTER FDA APPROVAL AWAY FROM CLASS 1. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $DFTX
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:09 PM
$CMPS $SNDL $CMPS Q1 2026 pending phase 3 topline imminent for COMP 360. I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class." Maybe this is the reason = "COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $DFTX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:18 AM
$SNDL Dumb ass shorts posting dumb shit, one little bible thumper study, & he thinks it nullifies an Executive order, no son... your stupid... @Slickerthanall187, and the dumbass puts, shorts shares borrowed, or sold calls... also stupid, every day that passes brings us closer to class 3, super smart guy. ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted 1 of them below, the breast cancer 1 , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:13 AM
$SNDL ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted ONE of them below, the breast cancer one , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." Aug 2025 https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
Iman133
Iman133 Jan. 13 at 8:49 PM
$BIB $IBB $LXRX I think it is good thing because FDA doesn’t understand what does the p-value mean. They reject when p= 0.051 and accept p=0.049 At least we get rid of p-value here
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 13 at 8:33 PM
$LXRX "FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials" Examples of Bayesian calculations used in various ways in clinical trials can include: Determining futility or success earlier in adaptive trials. Informing design elements like dose selection in subsequent trials. Incorporating information from other sources, such as previous clinical study data, real-world evidence, and external or nonconcurrent controls. Facilitating subgroup analyses. Supporting primary inference in a trial. The guidance provides recommendations on the appropriate use of Bayesian methods, with an emphasis on the use of these methods to support primary inference. Bayesian methods may be especially valuable for sponsors targeting rare or pediatric indications, where patient populations are smaller. https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials $IBB $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 8 at 2:50 PM
$LXRX $NVO is flying, wow.... good for us. "Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20256:40 AM PDT Updated March 28, 2025" https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ $VTYX $LLY $BIB
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 7 at 2:24 PM
$CMPS I'm ready baby, let's go $DFTX $ATAI $BIB https://lifescievents.com/event/q0v8tp3/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 7 at 3:27 AM
$CMPS Laying the groundwork ... News Today: Plus Investor Meeting Tomorrow: "Radial is building a national network of clinics across the U.S., delivering interventional, evidence-based treatments for mental health conditions. The co-founders have a mission-driven background in designing customer-centric care and building systems to enable operational scalability. Most notably, executive chairman Elliot Cohen co-founded PillPack, an e-commerce pharmacy sold to Amazon to become Amazon Pharmacy. Radial currently operates across five states and provides virtual assessments across the U.S. Together, Compass and Radial will explore how investigational COMP360 synthetic psilocybin treatment will fit into a growing national network of clinics such as Radial’s, with the aim of enabling a seamless integration at launch." https://finance.yahoo.com/news/compass-pathways-establishes-strategic-collaboration-113000360.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAAIKgBSZ5jd8U-RDluqrgMvGng2ii4QhfEEksut1pXaD6FaV5a4t3R5azmlAwehgC14Tc1ZosX2-qdlDpu5HZ6LFtXLrw_CX-TIq4wjtOw_sMEp9rp24_ZVarvGH4J2xIRGCAQsvf6pjvakh0PZu8OoRKNFZFKhHKbLxFhcFQtur Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Host-Webinar-on-Commercial-Preparations-for-Treatment-Resistant-Depression-TRD-and-Clinical-Trial-Plans-for-Post-Traumatic-Stress-Disorder-PTSD-on-January-7-2026-1000am-ET/default.aspx $ATAI $DFTX $BIB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 6:09 PM
$BIB RSI: 40.15, MACD: 0.6778 Vol: 1.97, MA20: 80.20, MA50: 76.77 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SaltSpeculator
SaltSpeculator Dec. 25 at 9:24 AM
$BIB Risk premia compress only when proof accumulates, since capital markets reward discipline over expansion for its own sake. The upside case requires evidence, not projection.
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 24 at 9:01 AM
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year $ABVX $BIB https://stocktwits.com/news/equity/markets/how-abivax-went-from-biotech-nobody-to-m-and-a-bullseye-after-a-single-blockbuster-readout/cLeso3JREHu
2 · Reply
2kaykim
2kaykim Nov. 26 at 5:37 PM
HOLY HELL+85% MOVE SINCE THE APRIL LOWS $XBI $IBB $LABU $BIB #BIOTECH
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Nov. 18 at 5:26 PM
$CMPS @SecKennedy Please watch: Psylocibin needs to be legalized as a therapy for Veterans and for the general public: Please watch this recent Netflix special: https://youtu.be/ao8tiqnuS3Y?si=TS13nrkwpReFTwhP @COMPASSPathway @ataibeckley are pioneers in this field. Please see their pipelines and please communicate with @MartyMakary and @US_FDA and have them also watch this documented Psylocibin therapeutics later confirm and validated with Stanford Brain analysis of pre and post treatment: https://scitechdaily.com/ibogaines-impact-alleviating-ptsd-depression-and-anxiety-in-special-ops-military-vets-with-traumatic-brain-injury/ $ATAI $BIB
0 · Reply
DinoMcnuggets
DinoMcnuggets Nov. 17 at 10:16 PM
$XBI $IBB $LABU $BIB Where were all the pumpers at 70? Now they are drawing triple bottom charts, and calling for a breakout AFTER the majority of the move has happened. Fundamentals are turning massively bearish for biotech again, with the TNX/DXY entering a new uptrend. Inflation is not contained, and the fed has officially given up. XBI Is overvalued by about 20 points at these based on the TIPS market. Buyout mania is bolstering valuations, but buyout mania is always a retail trap. When big pharma closes their pocket books, fundamentals will take over real fast.
4 · Reply
JFDI
JFDI Nov. 17 at 5:49 PM
$BIB $IBB $LABU $XBI
0 · Reply
2kaykim
2kaykim Nov. 17 at 5:46 PM
Biotech breaking out after putting in MULTI-YEAR TRIPLE BOTTOM. Biotech is +70% since the April lows & 50% away from 2021-ATH level $XBI $IBB $LABU $BIB
0 · Reply